Ebola primary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ebola}} | {{Ebola}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 11: | Line 8: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Ebola| ]] | [[Category:Ebola| ]] | ||
| Line 19: | Line 15: | ||
[[Category:Zoonoses]] | [[Category:Zoonoses]] | ||
[[Category:Hemorrhagic fevers]] | [[Category:Hemorrhagic fevers]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 18:35, 14 December 2012
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola primary prevention On the Web |
|
American Roentgen Ray Society Images of Ebola primary prevention |
|
Risk calculators and risk factors for Ebola primary prevention |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vaccines have been produced for both Ebola [1] and Marburg[2] that were 99% effective in protecting a group of monkeys from the disease. These vaccines are based on either a recombinant Vesicular stomatitis virus or a recombinant Adenovirus[3] carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at NIAID in 2003, have so far not reported any successes.[4] The biggest problem with the vaccine is that unless the patient is given it near the onset of the virus (1-4 days after the symptoms begin) then there will be too much damage to the human body to repair, ie: ruptured arteries and capillaries, vomiting, and other symptoms which may still cause enough harm to kill or seriously traumatize the patient.
References
- ↑ Jones, Steven (2005). "Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses". Nature Medicine. 11 (7): 786–790. doi:10.1038/nm1258. Unknown parameter
|coauthors=ignored (help) - ↑ Hevey, M (1998). "Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates". Virology. 251 (1): 28–37. doi:10.1006/viro.1998.9367. Unknown parameter
|coauthors=ignored (help) - ↑ Sullivan, Nancy (2003). "Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates". Nature. 424 (6949): 681–684. doi:10.1038/nature01876. Unknown parameter
|coauthors=ignored (help) - ↑ "NIAID Ebola Vaccine Enters Human Trial" (Press release). National Institute of Allergy and Infectious Diseases. 2003-11-18.